Welcome to our weekly roundup of CBD and hemp-related legal and regulatory news:
USPS reminds carriers about mail restrictions for CBD products
Products made with CBD oil have become popular, but there are restrictions when it comes to mailing
Continue Reading CBD and Hemp Legal and Regulatory Roundup
The FTC announced yesterday settlements with six companies accused of making a broad range of unsubstantiated health claims, including that CBD can treat cancer, heart disease, hypertension, Alzheimer’s disease, bipolar disorder, and chronic pain, among others. Nicknamed, “Operation CBDeceit,” the
Continue Reading FTC’s CBD Crackdown: Something Old and Something New
On May 22, Central California District Court Judge Virginia A. Phillips granted CBD retailer CV Sciences, Inc.’s (CV Sciences) request to stay the case of Colette et al. v. CV Sciences Inc., Case No. 2:19-cv-10227 (C.D. Cal), until the
Continue Reading Another Federal Court Halts False Advertising Case Pending FDA Review of CBD
Earlier this week, federal regulators continued their efforts to combat the spread of products featuring allegedly false and misleading claims that products can diagnose, treat, cure, or prevent COVID-19. In warning letters issued to CBD Gaze, Alternavita, Musthavemom.com
Continue Reading FDA and FTC Joint Warning Letters Target Amazon Affiliates Making False COVID-19 Claims
On April 29, the National Advertising Division (“NAD”) recommended that Talyoni Professional, LLC and its affiliate, Ecoco, Inc. (collectively “Talyoni”) discontinue express claims that the companies’ cosmetic and wellness products contain CBD, as well as product performance claims based on
Continue Reading The Proof Is In The Product: National Advertising Division (NAD) Recommends CBD Company Discontinue Claims
In a somewhat mixed decision for cannabis company defendants, a false advertising class action lawsuit will proceed in the Southern District of Florida – and not be halted while waiting for guidance from the FDA – although some of the
Continue Reading Florida Court Permits CBD Mislabeling Case to Proceed
As we have written about here and on our sister blog, Ad Law Access, regulators have wasted no time in taking enforcement actions against companies’ alleged false marketing around COVID-19. Just today, the Office of the New York Attorney
Continue Reading New York Joins the CBD COVID-19 Enforcement Fray
In the midst of continued enforcement regarding coronavirus marketing, FDA sent a warning letter to NeuroXPF concerning advertising for its CBD products alleging that they can boost immune systems to help consumers avoid contracting the virus. Citing the need to
Continue Reading CBD Manufacturer Not Immune From FDA Enforcement For COVID-19 Claims
Earlier this week, FDA sent its status report regarding a potential CBD enforcement discretion policy to Congress. As we wrote here, FDA was required to issue the report per the Joint Explanatory Statement attached to the 2020 Ag Appropriations
Continue Reading FDA Sends CBD Status Report to Congress; Market Clarity Remains Elusive
Over the past few years, a handful of law firms have filed thousands of lawsuits over website accessibility issues. This has been a lucrative business for these firms. Many of these suits are essentially cut-and-paste jobs, and the recipients often
Continue Reading Cannabis Companies Beware: You Can Get Sued If Your Website Isn’t Compliant With the Americans With Disabilities Act
